TY - JOUR
T1 - Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
AU - Eads, Jennifer R.
AU - Halfdanarson, Thorvardur R.
AU - Asmis, Tim
AU - Belizzi, Andrew M.
AU - Bergsland, Emily K.
AU - Dasari, Arvind
AU - El-Haddad, Ghassan
AU - Frumovitz, Michael
AU - Meyer, Joshua
AU - Mittra, Erik
AU - Myrehaug, Sten
AU - Nakakura, Eric
AU - Raj, Nitya
AU - Soares, Heloisa P.
AU - Untch, Brian
AU - Vijayvergia, Namrata
AU - Chan, Jennifer A.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.
AB - High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.
KW - high-grade
KW - neuroendocrine carcinoma
KW - neuroendocrine tumors
KW - recommendations
UR - http://www.scopus.com/inward/record.url?scp=85164302234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164302234&partnerID=8YFLogxK
U2 - 10.1530/ERC-22-0206
DO - 10.1530/ERC-22-0206
M3 - Article
C2 - 37184955
AN - SCOPUS:85164302234
SN - 1351-0088
VL - 30
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
IS - 8
ER -